Mantle Cell Lymphoma - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 426 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mantle Cell Lymphoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Mantle Cell Lymphoma - Pipeline Review, H1 2016', provides an overview of the Mantle Cell Lymphoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Mantle Cell Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Mantle Cell Lymphoma - Overview 11
Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 12
Mantle Cell Lymphoma - Therapeutics under Development by Companies 13
Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
Mantle Cell Lymphoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Mantle Cell Lymphoma - Products under Development by Companies 20
Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 25
Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 26
AB Science SA 26
AbbVie Inc. 27
Acetylon Pharmaceuticals, Inc. 28
Actinium Pharmaceuticals, Inc. 29
Affimed Therapeutics AG 30
Amgen Inc. 31
Astellas Pharma Inc. 32
Astex Pharmaceuticals, Inc. 33
Bayer AG 34
Bristol-Myers Squibb Company 35
Celgene Corporation 36
Cellular Biomedicine Group, Inc. 37
Eisai Co., Ltd. 38
EpiZyme, Inc. 39
Fate Therapeutics, Inc. 40
Genentech, Inc. 41
Gilead Sciences, Inc. 42
GlaxoSmithKline Plc 43
Hutchison MediPharma Limited 44
ImmunoGen, Inc. 45
Immunomedics, Inc. 46
Incyte Corporation 47
Inflection Biosciences Limited 48
Johnson & Johnson 49
Juno Therapeutics Inc. 50
Karyopharm Therapeutics, Inc. 51
Kite Pharma, Inc. 52
Les Laboratoires Servier SAS 53
LFB S.A. 54
MedImmune, LLC 55
Merck & Co., Inc. 56
Millennium Pharmaceuticals, Inc. 57
MorphoSys AG 58
Nordic Nanovector ASA 59
Novartis AG 60
Onconova Therapeutics, Inc. 61
Onyx Pharmaceuticals, Inc. 62
Pfizer Inc. 63
Pharmacyclics, Inc. 64
Portola Pharmaceuticals, Inc. 65
Seattle Genetics, Inc. 66
Selvita S.A. 67
Sorrento Therapeutics, Inc. 68
Stemline Therapeutics, Inc. 69
Takeda Pharmaceutical Company Limited 70
TG Therapeutics, Inc. 71
Mantle Cell Lymphoma - Therapeutics Assessment 72
Assessment by Monotherapy Products 72
Assessment by Combination Products 73
Assessment by Target 74
Assessment by Mechanism of Action 78
Assessment by Route of Administration 82
Assessment by Molecule Type 84
Drug Profiles 86
(INCB-039110 + INCB-040093) - Drug Profile 86
13197 - Drug Profile 87
AB-8779 - Drug Profile 89
abexinostat hydrochloride - Drug Profile 90
acalabrutinib - Drug Profile 92
acalisib - Drug Profile 95
ACY-241 - Drug Profile 96
ACY-775 - Drug Profile 98
AFM-11 - Drug Profile 99
agatolimod sodium - Drug Profile 100
alisertib - Drug Profile 102
AMG-319 - Drug Profile 107
ASN-002 - Drug Profile 108
AT-7519 - Drug Profile 109
avicin d - Drug Profile 112
bendamustine hydrochloride - Drug Profile 113
Betalutin - Drug Profile 116
BGB-3111 - Drug Profile 118
BLyS-gel - Drug Profile 119
BMS-986016 - Drug Profile 120
buparlisib hydrochloride - Drug Profile 121
carfilzomib - Drug Profile 125
CBM-C19.1 - Drug Profile 129
CBM-C20.1 - Drug Profile 130
CC-122 - Drug Profile 132
Cellular Immunotherapy for Oncology - Drug Profile 134
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 135
Cellular Immunotherapy to Target ROR1 for Oncology - Drug Profile 136
cerdulatinib - Drug Profile 137
copanlisib hydrochloride - Drug Profile 139
daratumumab - Drug Profile 143
denintuzumab mafodotin - Drug Profile 147
E-7449 - Drug Profile 148
entospletinib - Drug Profile 149
epratuzumab - Drug Profile 150
EPZ-015666 - Drug Profile 155
FT-1050 - Drug Profile 156
HMPL-523 - Drug Profile 159
IBL-301 - Drug Profile 160
ibrutinib - Drug Profile 162
idelalisib - Drug Profile 169
IGN-002 - Drug Profile 172
IMGN-529 - Drug Profile 173
IMMU-114 - Drug Profile 175
INA-01 - Drug Profile 176
INCB-40093 - Drug Profile 177
inebilizumab - Drug Profile 178
inebilizumab + MEDI-0680 - Drug Profile 180
inebilizumab + rituximab - Drug Profile 181
itacitinib adipate - Drug Profile 182
ixazomib citrate - Drug Profile 184
JCAR-014 - Drug Profile 188
JCAR-015 - Drug Profile 189
JCAR-017 - Drug Profile 191
JNJ-64052781 - Drug Profile 192
KTEC-19 - Drug Profile 193
LAM-002A - Drug Profile 196
lenalidomide - Drug Profile 197
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 202
Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 203
MOR-208 - Drug Profile 204
ON-123300 - Drug Profile 206
ONC-201 - Drug Profile 207
OSU-2S - Drug Profile 210
pembrolizumab - Drug Profile 212
polatuzumab vedotin - Drug Profile 222
ribociclib - Drug Profile 224
S-055746 - Drug Profile 227
SEL-120 - Drug Profile 228
SEL-12034 - Drug Profile 230
SEL-24B489 - Drug Profile 232
selinexor - Drug Profile 234
SGN-CD70A - Drug Profile 240
SL-101 - Drug Profile 241
TAK-659 - Drug Profile 242
temsirolimus - Drug Profile 243
TGR-1202 - Drug Profile 245
tisagenlecleucel-T - Drug Profile 248
tretinoin - Drug Profile 251
ublituximab - Drug Profile 252
venetoclax - Drug Profile 255
vorinostat - Drug Profile 259
Mantle Cell Lymphoma - Recent Pipeline Updates 263
Mantle Cell Lymphoma - Dormant Projects 408
Mantle Cell Lymphoma - Discontinued Products 410
Mantle Cell Lymphoma - Product Development Milestones 411
Featured News & Press Releases 411
Appendix 419
Methodology 419
Coverage 419
Secondary Research 419
Primary Research 419
Expert Panel Validation 419
Contact Us 419
Disclaimer 420

List of Tables
Number of Products under Development for Mantle Cell Lymphoma, H1 2016 17
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Number of Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H1 2016 22
Comparative Analysis by Late Stage Development, H1 2016 23
Comparative Analysis by Clinical Stage Development, H1 2016 24
Comparative Analysis by Early Stage Development, H1 2016 25
Products under Development by Companies, H1 2016 26
Products under Development by Companies, H1 2016 (Contd..1) 27
Products under Development by Companies, H1 2016 (Contd..2) 28
Products under Development by Companies, H1 2016 (Contd..3) 29
Products under Development by Companies, H1 2016 (Contd..4) 30
Products under Investigation by Universities/Institutes, H1 2016 31
Mantle Cell Lymphoma - Pipeline by AB Science SA, H1 2016 32
Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H1 2016 33
Mantle Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 34
Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 35
Mantle Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016 36
Mantle Cell Lymphoma - Pipeline by Amgen Inc., H1 2016 37
Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016 38
Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 39
Mantle Cell Lymphoma - Pipeline by Bayer AG, H1 2016 40
Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 41
Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H1 2016 42
Mantle Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 43
Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016 44
Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H1 2016 45
Mantle Cell Lymphoma - Pipeline by Fate Therapeutics, Inc., H1 2016 46
Mantle Cell Lymphoma - Pipeline by Genentech, Inc., H1 2016 47
Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 48
Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016 49
Mantle Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016 50
Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016 51
Mantle Cell Lymphoma - Pipeline by Immunomedics, Inc., H1 2016 52
Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H1 2016 53
Mantle Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H1 2016 54
Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H1 2016 55
Mantle Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 56
Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 57
Mantle Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016 58
Mantle Cell Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016 59
Mantle Cell Lymphoma - Pipeline by LFB S.A., H1 2016 60
Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2016 61
Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 62
Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 63
Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H1 2016 64
Mantle Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016 65
Mantle Cell Lymphoma - Pipeline by Novartis AG, H1 2016 66
Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2016 67
Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2016 68
Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H1 2016 69
Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016 70
Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 71
Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 72
Mantle Cell Lymphoma - Pipeline by Selvita S.A., H1 2016 73
Mantle Cell Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016 74
Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016 75
Mantle Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 76
Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 77
Assessment by Monotherapy Products, H1 2016 78
Assessment by Combination Products, H1 2016 79
Number of Products by Stage and Target, H1 2016 81
Number of Products by Stage and Mechanism of Action, H1 2016 85
Number of Products by Stage and Route of Administration, H1 2016 89
Number of Products by Stage and Molecule Type, H1 2016 91
Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 269
Mantle Cell Lymphoma - Dormant Projects, H1 2016 414
Mantle Cell Lymphoma - Dormant Projects (Contd..1), H1 2016 415
Mantle Cell Lymphoma - Discontinued Products, H1 2016 416